Phase 3Recruiting
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer
- Sponsor
- BioNTech SE (Industry)
- Enrolment
- 621 planned
- Conditions
- Extensive-stage Small-cell Lung Cancer
- Interventions
- Pumitamig; Atezolizumab; Etoposide; Carboplatin (or cisplatin if carboplatin is not tolerated)
- Ages
- adults, older adults
- Registry
- NCT06712355, CTIS2024-515765-34-00
Full record on ClinicalTrials.gov
From the registry
This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untreated extensive-stage small-cell lung cancer (ES-SCLC).
Primary outcomes
- Overall survival (OS)
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered